Kindred getting out of nursing home business

Louisville, Kentucky-based Kindred Healthcare will be divesting its skilled nursing facilities to focus on more profitable business segments like long-term acute care and rehabilitation hospitals.

Kindred owns 91 nursing homes and is the company’s smallest business segment. It’s also on the decline, with third quarter earnings before interest, taxes, depreciation and amortization (EBITDA) declining 16.7 percent from the same quarter in 2015.

“Our strategic decision to exit the skilled nursing facility business as an owner and operator is the final step in a process that began years ago when Kindred operated approximately 300 skilled nursing facilities,” Kindred CEO Benjamin Braier said in a statement. “This decision will reduce annual rent obligations by approximately $90 million and annual capital expenditures by approximately $30 million. In addition, Kindred will optimize its overhead structure by eliminating approximately $70 million to $100 million of divisional and corporate overhead above the facility level, much of which is associated with supporting our skilled nursing facilities.”

Overall, the company reported a $671 million loss in the quarter

While Kindred had been downsizing its nursing home business, it had remained active in the industry. The U.S. Supreme Court agreed in October to take the company’s case defending the validity of arbitration agreements with nursing home residents.

No timeline has given for when Kindred will have completed the divesture of the facilities. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.